ION363 + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Jun 14, 2021 → Mar 1, 2028
NCT ID
NCT04768972About ION363 + Placebo
ION363 + Placebo is a phase 3 stage product being developed by Ionis Pharmaceuticals for Amyotrophic Lateral Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT04768972. Target conditions include Amyotrophic Lateral Sclerosis.
What happened to similar drugs?
2 of 17 similar drugs in Amyotrophic Lateral Sclerosis were approved
Approved (2) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04768972 | Phase 3 | Active |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 17 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 35 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 18 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 38 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 38 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 40 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 35 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 36 |
| TCH346 | Novartis | Phase 2 | 35 |
| VHB937 | Novartis | Phase 2 | 39 |
| TCH346 | Novartis | Phase 2 | 35 |
| TCH346 | Novartis | Phase 2 | 35 |
| BLZ945 | Novartis | Phase 2 | 27 |
| TRO19622 | Roche | Phase 2/3 | 38 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 40 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 28 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 35 |